Tarsy D, Kaufman D, Sethi K D, Rivner M H, Molho E, Factor S
Department of Neurology, Beth Israel Deconess Medical Center, Boston, Massachusetts, USA.
Clin Neuropharmacol. 1997 Feb;20(1):90-3. doi: 10.1097/00002826-199702000-00012.
Tardive dystonia is a form of tardive dyskinesia for which there is little satisfactory treatment. We reviewed our experience at four movement disorder centers in the treatment of tardive dystonia with botulinum toxin A (BTX-A). Thirty-four patients with relatively localized tardive dystonia unresponsive to oral medications were treated with injections of BTX-A into dystonia muscles. Cervical dystonia was the most frequent manifestation of tardive dystonia in this group of patients. There was marked or moderate improvement in 29 of 34 patients. Eighteen of 24 patients with cervical dystonia showed either marked or moderate improvement. In this retrospective review, BTX-A provided useful symptomatic treatment for localized dystonia in patients with tardive dystonia unresponsive to other treatment. A controlled, prospective trial of BTX-A in tardive dystonia is warranted.
迟发性肌张力障碍是迟发性运动障碍的一种形式，对此几乎没有令人满意的治疗方法。我们回顾了我们在四个运动障碍中心用A型肉毒毒素（BTX-A）治疗迟发性肌张力障碍的经验。34例对口服药物无反应的相对局限性迟发性肌张力障碍患者接受了向肌张力障碍肌肉注射BTX-A的治疗。颈部肌张力障碍是该组患者中迟发性肌张力障碍最常见的表现。34例患者中有29例有显著或中度改善。24例颈部肌张力障碍患者中有18例有显著或中度改善。在这项回顾性研究中，BTX-A为对其他治疗无反应的迟发性肌张力障碍患者的局限性肌张力障碍提供了有效的对症治疗。有必要对BTX-A治疗迟发性肌张力障碍进行对照的前瞻性试验。
